Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SAINT: A Phase 1/2 Study of Safe Amounts of IPLIMUMAB, NIVOLUMAB and TRABECTEDIN for Previously Treated Advanced Soft Tissue Sarcoma (STS)

NCT03138161 is registered in ClinicalTrials.gov with Sarcoma Oncology Research Center, LLC as lead sponsor.

NCT NCT03138161
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03138161 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SAINT: A Phase 1/2 Study of Safe Amounts of IPLIMUMAB, NIVOLUMAB and TRABECTEDIN for Previously Treated Advanced Soft Tissue Sarcoma (STS)
Lead sponsor
Sarcoma Oncology Research Center, LLC
Phase
Phase 1/2
Overall status
Recruiting
Start date
April 13, 2017
Completion date
July 31, 2031
Enrollment
250 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced soft tissue sarcoma, metastatic soft tissue sarcoma